Yangyin Shugan capsule ameliorates premature ovarian insufficiency via dual receptor-mediated cascade in rats

Jiarui Hou, Xuchun Huang, Xiaojing Cao, Fangping Cheng, Xiaoyun Wang
In: Phytomedicine · 2025 · vol. 147 , pp. 157139 · doi:10.1016/j.phymed.2025.157139 · PMID:40886475 · W4412999657
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

The Yangyin Shugan capsule improved premature ovarian insufficiency in rats by modulating the GnRHR and ERα signaling pathways.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BackgroundPremature ovarian insufficiency (POI) is a significant health issue for women under 40, characterized by declining ovarian function, hormonal imbalance, and various long-term health consequences. Current hormone replacement therapy (HRT) has limitations and potential risks. Thus, there is a need for safer and more effective therapeutic alternatives. Yangyin Shugan Capsule (YYSG), a traditional Chinese medicine formula, has shown clinical efficacy in treating POI. This study aimed to investigate the protective effects and the dual receptor-mediated cascade regulation mechanisms of YYSG in a rat model of POI induced by VCD combined with chronic unpredictable mild stress (CUMS), which better simulates the complex etiology of human POI.MethodsYYSG chemical components were first identified using LC-MS/MS. Subsequently, network pharmacology analysis was performed by predicting targets for these identified components and intersecting them with known POI disease targets to identify common targets and key pathways. A POI rat model was established using VCD injection followed by CUMS. Rats were treated with YYSG (low, medium, high dose), Estrogen Valerate (EV), or vehicle. General condition, body weight, estrous cycle, ovarian morphology (HE staining, follicle count), and serum hormones (FSH, E2, AMH) were assessed. The expression of estrogen receptors (ER-α, ER-β) and key molecules in the PI3K/AKT/mTOR and autophagy/apoptosis pathways were analyzed in ovarian tissue by immunohistochemistry, Western Blot, and qPCR. In vitro studies examined YYSG serum's effect on granulosa cell proliferation and the involvement of ER and PI3K pathways using inhibitors.ResultsLC-MS/MS identified 25 active components in YYSG. Network pharmacology analysis, initiated from these components, predicted 314 intersecting targets and significantly enriched the PI3K-Akt signaling pathway, with ESR1 (encoding ER-α) among the core targets. The VCD+CUMS model successfully induced POI characteristics in rats. YYSG treatment, especially medium and high doses, significantly improved general status, body weight, restored hormonal balance (decreased FSH, increased E2/AMH), and ameliorated ovarian morphology (increased follicle counts, decreased atresia), comparable to EV. Mechanistically, YYSG upregulated ER-α/β expression and activated the PI3K/AKT/mTOR pathway while inhibiting autophagy and apoptosis in ovarian tissue. In vitro, YYSG serum promoted granulosa cell proliferation, and this effect was significantly blocked by ER and PI3K inhibitors, highlighting the involvement of the ER-mediated PI3K pathway. YYSG showed no obvious toxicity in safety tests.ConclusionThis study demonstrates that Yangyin Shugan Capsule (YYSG) effectively alleviates VCD+CUMS-induced premature ovarian insufficiency in rats. Crucially, this research is the first to elucidate that YYSG activates the PI3K/AKT/mTOR pathway via a dual-receptor (ERα/ERβ)-mediated cascade regulation. This mechanism collectively inhibits autophagy and apoptosis in ovarian cells and promotes follicular development. A novel finding also includes the positive feedback regulation of ERα by PI3K, which establishes a self-amplifying protective signaling network. These results offer robust experimental support for YYSG as a promising, safe, and efficacious therapeutic strategy for POI, holding significant potential for clinical application.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (41)

Source provenance

openalex
last seen: 2026-05-11T06:54:00.798642+00:00
unpaywall
last seen: 2026-09-04T06:34:25.427880+00:00
License: CC0 · commercial use OK